Literature DB >> 56059

HL-A8 and LD-8a in patients with myasthenia gravis.

E Möller, L Hammarström, E Smith, G Matell.   

Abstract

The frequency of HL-A8 in myasthenia gravis is markedly increased in women (60-80%) but not in men. The MLC determinant, LD-8a, is frequently associated with HL-A8. Of the 37 female MS patients, 15 were LD-8a positive (41%), whereas of the males only one of seven was LD-8a positive. The frequency of HL-A8 was 68% in women and 29% in men with the disease. We therefore conclude that the gene which is responsible for the increased susceptibility to myasthenia gravis in women and which is present in the MHS region, is more closely linked to the SD-2 than to the LD-1 locus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56059     DOI: 10.1111/j.1399-0039.1976.tb01027.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  5 in total

1.  Immune disease and HLA associations with myasthenia gravis.

Authors:  P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

2.  HLA-types, C-peptide and insulin antibodies in juvenile diabetes.

Authors:  J Ludvigsson; J Säfwenberg; L G Heding
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

3.  An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes.

Authors:  M A Degli-Esposti; A Andreas; F T Christiansen; B Schalke; E Albert; R L Dawkins
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Iridocyclitis in black Americans: association with HLA B8 suggests an autoimmune aetiology.

Authors:  R B Nussenblatt; K K Mittal
Journal:  Br J Ophthalmol       Date:  1981-05       Impact factor: 4.638

5.  Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis.

Authors:  B Carlsson; J Wallin; R Pirskanen; G Matell; C I Smith
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.